MX2019006513A - Formulaciones y terapias de reemplazo de hormonas de combinacion natural. - Google Patents

Formulaciones y terapias de reemplazo de hormonas de combinacion natural.

Info

Publication number
MX2019006513A
MX2019006513A MX2019006513A MX2019006513A MX2019006513A MX 2019006513 A MX2019006513 A MX 2019006513A MX 2019006513 A MX2019006513 A MX 2019006513A MX 2019006513 A MX2019006513 A MX 2019006513A MX 2019006513 A MX2019006513 A MX 2019006513A
Authority
MX
Mexico
Prior art keywords
therapies
hormone replacement
natural combination
combination hormone
replacement formulations
Prior art date
Application number
MX2019006513A
Other languages
English (en)
Spanish (es)
Inventor
A Bernick Brian
M Amadio Julia
Mirkin Sebastian
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of MX2019006513A publication Critical patent/MX2019006513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019006513A 2016-12-05 2017-12-05 Formulaciones y terapias de reemplazo de hormonas de combinacion natural. MX2019006513A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US201762481060P 2017-04-03 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (1)

Publication Number Publication Date
MX2019006513A true MX2019006513A (es) 2019-08-14

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006513A MX2019006513A (es) 2016-12-05 2017-12-05 Formulaciones y terapias de reemplazo de hormonas de combinacion natural.

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020504093A (cg-RX-API-DMAC10.html)
KR (1) KR20200018383A (cg-RX-API-DMAC10.html)
CN (1) CN110290793A (cg-RX-API-DMAC10.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC10.html)
IL (1) IL267023A (cg-RX-API-DMAC10.html)
MX (1) MX2019006513A (cg-RX-API-DMAC10.html)
RU (1) RU2019115913A (cg-RX-API-DMAC10.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR100562A1 (es) * 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19
KR20200018383A (ko) 2020-02-19
JP2020504093A (ja) 2020-02-06
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2016014281A (es) Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
EP4272731A3 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
GEP20247693B (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
IL276169A (en) Peptide YY pharmacological formulations, compositions and methods
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX365818B (es) Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
MY188879A (en) Glycan therapeutics and related methods thereof
EA201891142A1 (ru) Контроль клеточных окислительно-восстановительных уровней
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
MX2015017655A (es) Modulador de receptores de estrogeno y uso del mismo.
IL270812B1 (en) Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease